429 related articles for article (PubMed ID: 27315514)
1. RANDOMIZED TRIAL OF D-CYCLOSERINE ENHANCEMENT OF COGNITIVE-BEHAVIORAL THERAPY FOR PANIC DISORDER.
Otto MW; Pollack MH; Dowd SM; Hofmann SG; Pearlson G; Szuhany KL; Gueorguieva R; Krystal JH; Simon NM; Tolin DF
Depress Anxiety; 2016 Aug; 33(8):737-45. PubMed ID: 27315514
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder.
Otto MW; Tolin DF; Simon NM; Pearlson GD; Basden S; Meunier SA; Hofmann SG; Eisenmenger K; Krystal JH; Pollack MH
Biol Psychiatry; 2010 Feb; 67(4):365-70. PubMed ID: 19811776
[TBL] [Abstract][Full Text] [Related]
3. No Effects of D-Cycloserine Enhancement in Exposure With Response Prevention Therapy in Panic Disorder With Agoraphobia: A Double-Blind, Randomized Controlled Trial.
Hofmeijer-Sevink MK; Duits P; Rijkeboer MM; Hoogendoorn AW; van Megen HJ; Vulink NC; Denys DA; van den Hout MA; van Balkom AJ; Cath DC
J Clin Psychopharmacol; 2017 Oct; 37(5):531-539. PubMed ID: 28820746
[TBL] [Abstract][Full Text] [Related]
4. Learn to forget: Does post-exposure administration of d-cycloserine enhance fear extinction in agoraphobia?
Pyrkosch L; Mumm J; Alt I; Fehm L; Fydrich T; Plag J; Ströhle A
J Psychiatr Res; 2018 Oct; 105():153-163. PubMed ID: 30237105
[TBL] [Abstract][Full Text] [Related]
5. D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial.
Siegmund A; Golfels F; Finck C; Halisch A; Räth D; Plag J; Ströhle A
J Psychiatr Res; 2011 Aug; 45(8):1042-7. PubMed ID: 21377691
[TBL] [Abstract][Full Text] [Related]
6. Enhancing panic and smoking reduction treatment with D-Cycloserine: A pilot randomized clinical trial.
Smits JAJ; Zvolensky MJ; Otto MW; Piper ME; Baird SO; Kauffman BY; Lee-Furman E; Alavi N; Dutcher CD; Papini S; Rosenfield B; Rosenfield D
Drug Alcohol Depend; 2020 Mar; 208():107877. PubMed ID: 32004998
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trial.
Nations KR; Smits JA; Tolin DF; Rothbaum BO; Hofmann SG; Tart CD; Lee A; Schipper J; Sjogren M; Xue D; Szegedi A; Otto MW
J Clin Psychiatry; 2012 May; 73(5):647-53. PubMed ID: 22394471
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders.
Ori R; Amos T; Bergman H; Soares-Weiser K; Ipser JC; Stein DJ
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007803. PubMed ID: 25957940
[TBL] [Abstract][Full Text] [Related]
9. D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial.
Andersson E; Hedman E; Enander J; Radu Djurfeldt D; Ljótsson B; Cervenka S; Isung J; Svanborg C; Mataix-Cols D; Kaldo V; Andersson G; Lindefors N; Rück C
JAMA Psychiatry; 2015 Jul; 72(7):659-67. PubMed ID: 25970252
[TBL] [Abstract][Full Text] [Related]
10. N-methyl-D-aspartate Partial Agonist Enhanced Intensive Cognitive-Behavioral Therapy of Panic Disorder in Adolescents.
Leyfer O; Carpenter A; Pincus D
Child Psychiatry Hum Dev; 2019 Apr; 50(2):268-277. PubMed ID: 30078111
[TBL] [Abstract][Full Text] [Related]
11. D-cycloserine augmentation of cognitive behavioral therapy for delusions: A randomized clinical trial.
Diminich ED; Dickerson F; Bello I; Cather C; Kingdon D; Rakhshan Rouhakhtar PJ; Hart KL; Li C; Troxel AB; Goff DC
Schizophr Res; 2020 Aug; 222():145-152. PubMed ID: 32591238
[TBL] [Abstract][Full Text] [Related]
12. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.
Mataix-Cols D; Fernández de la Cruz L; Monzani B; Rosenfield D; Andersson E; Pérez-Vigil A; Frumento P; de Kleine RA; Difede J; Dunlop BW; Farrell LJ; Geller D; Gerardi M; Guastella AJ; Hofmann SG; Hendriks GJ; Kushner MG; Lee FS; Lenze EJ; Levinson CA; McConnell H; Otto MW; Plag J; Pollack MH; Ressler KJ; Rodebaugh TL; Rothbaum BO; Scheeringa MS; Siewert-Siegmund A; Smits JAJ; Storch EA; Ströhle A; Tart CD; Tolin DF; van Minnen A; Waters AM; Weems CF; Wilhelm S; Wyka K; Davis M; Rück C; ; Altemus M; Anderson P; Cukor J; Finck C; Geffken GR; Golfels F; Goodman WK; Gutner C; Heyman I; Jovanovic T; Lewin AB; McNamara JP; Murphy TK; Norrholm S; Thuras P
JAMA Psychiatry; 2017 May; 74(5):501-510. PubMed ID: 28122091
[TBL] [Abstract][Full Text] [Related]
13. Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for pediatric posttraumatic stress.
Scheeringa MS; Weems CF
J Child Adolesc Psychopharmacol; 2014 Mar; 24(2):69-77. PubMed ID: 24506079
[TBL] [Abstract][Full Text] [Related]
14. Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy.
Farrell LJ; Waters AM; Boschen MJ; Hattingh L; McConnell H; Milliner EL; Collings N; Zimmer-Gembeck M; Shelton D; Ollendick TH; Testa C; Storch EA
Depress Anxiety; 2013 Aug; 30(8):723-31. PubMed ID: 23722990
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA
JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832
[TBL] [Abstract][Full Text] [Related]
16. D-Cycloserine augmentation of cognitive behavior therapy for pediatric OCD: Predictors and moderators of outcome.
Wilhelm S; Berman N; Small BJ; Porth R; Storch EA; Geller D
J Affect Disord; 2018 Dec; 241():454-460. PubMed ID: 30149332
[TBL] [Abstract][Full Text] [Related]
17. D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions.
Smits JA; Rosenfield D; Otto MW; Marques L; Davis ML; Meuret AE; Simon NM; Pollack MH; Hofmann SG
J Psychiatr Res; 2013 Oct; 47(10):1455-61. PubMed ID: 23870811
[TBL] [Abstract][Full Text] [Related]
18. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial.
Simon NM; Otto MW; Worthington JJ; Hoge EA; Thompson EH; Lebeau RT; Moshier SJ; Zalta AK; Pollack MH
J Clin Psychiatry; 2009 Nov; 70(11):1563-70. PubMed ID: 19814948
[TBL] [Abstract][Full Text] [Related]
19. Enhancing panic and smoking reduction treatment with d-cycloserine: Study protocol for a randomized controlled trial.
Smits JA; Kauffman BY; Lee-Furman E; Zvolensky MJ; Otto MW; Piper ME; Powers MB; Rosenfield D
Contemp Clin Trials; 2016 May; 48():46-51. PubMed ID: 27015966
[TBL] [Abstract][Full Text] [Related]
20. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder.
Storch EA; Murphy TK; Goodman WK; Geffken GR; Lewin AB; Henin A; Micco JA; Sprich S; Wilhelm S; Bengtson M; Geller DA
Biol Psychiatry; 2010 Dec; 68(11):1073-6. PubMed ID: 20817153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
